Search - tctmd.com

Displaying 141 - 160 of 191

Sort: Relevancy | Date

Presentation AHA 2017

Impact of Regionalization of ST Elevation Myocardial Infarction Care

Presenter: James G. Jollis

November 14, 2017

Presentation AHA 2017

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Presenter: Mar Pujades-Rodriguez

November 14, 2017

Presentation AHA 2017

The POISE-2 PCI Substudy

Presenter: Michelle M. Graham

November 14, 2017

Presentation AHA 2017

Subgroup Analysis from the RE-DUAL PCI Trial

Presenter: Jonas Oldgren

November 14, 2017

Presentation AHA 2017

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Presenter: Kenneth W. Mahaffey

November 14, 2017

Presentation AHA 2017

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Presenter: Louise Bowman

November 14, 2017

Presentation AHA 2017

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Presenter: Steven Weisbord

November 13, 2017

Presentation AHA 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presenter: Akihiko Nogami

November 13, 2017

Presentation AHA 2017

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

Presenter: Zuzana Motovska

November 11, 2017

Presentation TCT 2017

Take-home Messages for Managing Aortic Valve Disease From the 2017 AHA/ACC Focused Update

Presenter: Martin B. Leon, Patrick T. O'Gara, Allan Schwartz

October 30, 2017

Presentation TCT 2017

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: AHA

Presenter: Wayne B. Batchelor, George A. Mensah, Robert A. Harrington

October 30, 2017

Presentation TVT 2017

The 2017 AHA/ACC Focused Update of the Guidelines for Managing Aortic Valve Disease: Take-home Messages for the Clinician

Presenter: Robert O. Bonow, Martin B. Leon, Allan Schwartz

June 15, 2017

Presentation AHA 2016

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Presenter: Dirk J. van Veldhuisen

November 16, 2016

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

Presentation AHA 2016

Arterial Revascularization Trial (ART)

Presenter: David P. Taggart

November 15, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

Presentation AHA 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presenter: Gilles Rioufol

November 15, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Advertisement

Impact of Regionalization of ST Elevation Myocardial Infarction Care

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

The POISE-2 PCI Substudy

Subgroup Analysis from the RE-DUAL PCI Trial

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

Take-home Messages for Managing Aortic Valve Disease From the 2017 AHA/ACC Focused Update

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: AHA

The 2017 AHA/ACC Focused Update of the Guidelines for Managing Aortic Valve Disease: Take-home Messages for the Clinician

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Arterial Revascularization Trial (ART)

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

FUnctional Testing Underlying REvascularization: The FUTURE trial

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content